Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Polatuzumab Vedotin plus Bendamustine and Rituximab versus Bendamustine and Rituximab alone in Chinese patients with relapsed or refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diffuse, Large B-Cell, Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2022-08-04